Finding new treatments for platinum-resistant ovarian cancer using T-cell therapy
Official title: Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer
Funded at University of California Los Angeles · NIH-11115806 · Data updated 2026-11-12
This study is looking for new ways to help patients with tough-to-treat ovarian cancer by analyzing their tumor samples to find specific targets that can be attacked by the immune system, which could lead to better treatments for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | June 18, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $681,544 |
| NIH project number | 5R01CA287673-02 |
| Project ID | NIH-11115806 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with platinum-resistant high-grade serous ovarian carcinoma who have experienced disease recurrence after initial platinum-based treatment.
✕Less likely to help
Patients with other types of ovarian cancer or those who have not been treated with platinum-based therapies may not benefit from this research.
What this research studies
This research focuses on developing T-cell receptor (TCR) therapies specifically for patients with platinum-resistant high-grade serous ovarian carcinoma (HGSOC), a challenging cancer with limited treatment options. The approach involves analyzing the unique variations in RNA and proteins produced by cancer cells to identify new targets for immunotherapy. By utilizing advanced long-read RNA sequencing, the researchers aim to uncover cancer-specific antigens that can be targeted by T-cells, potentially leading to more effective treatments for this aggressive cancer. Patients will be involved in the study as their tumor samples will be analyzed to discover these new therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for patients with platinum-resistant ovarian cancer, improving their treatment outcomes.
How similar studies have gone: Other research has shown promise in utilizing T-cell therapies and RNA sequencing for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Memarzadeh, Sanaz — University of California Los Angeles
- Study coordinator: Memarzadeh, Sanaz
Related research
Other NIH-funded projects on the same topics.
-
Mitotic MTH1 Inhibitors for Platinum-Resistant Ovarian Cancer
A treatment approach targeting a specific cancer cell weakness (MTH1) to help women whose ovarian cancer stopped responding to platinum-based therapy.
-
Cirtuvivint plus PARP inhibitor in BRCA/HRD ovarian cancer
A new treatment approach combines a CLK/DYRK inhibitor with a PARP inhibitor to help women with BRCA mutations or HRD ovarian cancer who have become resistant to platinum therapy.
-
Targeting cancer-specific protein variants to guide T-cell therapy in platinum-resistant ovarian cancer
Aims to find unique protein variants in platinum-resistant ovarian cancer to guide T-cell receptor therapy for patients.
-
Why some ovarian cancers resist platinum chemotherapy: changes in tumor metabolism
This project looks at how ovarian tumors change their metabolism when they stop responding to platinum chemotherapy and seeks new targets and markers to help women with recurrent high-grade serous ovarian cancer.
-
Cirtuvivint plus olaparib for BRCA/HRD ovarian cancer that stopped responding to platinum
This work adds cirtuvivint to the PARP drug olaparib to try to help people with BRCA-mutated or homologous recombination–deficient ovarian cancer that no longer responds to platinum chemotherapy.
-
Exploring how ovarian cancer cells change metabolism to resist treatment
This study is looking into why some patients with high-grade serous ovarian cancer stop responding to standard platinum treatments, and it hopes to find new ways to help those patients by understanding how their cancer cells change and adapt.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.